Efficacy of aprepitant in preventing nausea and vomiting due to high-dose melphalan-based conditioning for allogeneic hematopoietic stem cell transplantation
- 12 March 2014
- journal article
- research article
- Published by Springer Nature in International Journal of Hematology
- Vol. 99 (4) , 457-462
Abstract
High-dose melphalan has been gaining recognition as a highly emetogenic agent used in hematopoietic stem cell transplantation (HSCT). The aim of this retrospective study was to elucidate the efficacy of aprepitant in preventing high-dose melphalan-induced emesis. Sixty patients who received melphalan (70 mg/m2/day, 2 days) and fludarabine (125 mg/m2/day, 5 days) as conditioning for allogeneic HSCT for hematological malignancies, and who received ondansetron and methylprednisolone as an antiemetic prophylaxis, were eligible. Twenty of these 60 patients also received aprepitant for 5 days (aprepitant group); the remaining 40 patients served as a control. The rates of complete response (CR), defined as no emesis without rescue medications, and complete protection (CP), defined as no emesis with or without rescue medications, were assessed between the two groups. The observation period was 12 days from the first day of melphalan administration. The CR and CP rates were significantly higher in the aprepitant group than in the control group during the observation period (35 % versus 10 %, P < 0.05; 85 % versus 33 %, P < 0.001; respectively). These results suggest that aprepitant in combination with ondansetron and steroid effectively ameliorates nausea and vomiting caused by the high-dose melphalan-based conditioning for allogeneic HSCT.Keywords
This publication has 28 references indexed in Scilit:
- Efficacy and Safety of Aprepitant in Allogeneic Hematopoietic Stem Cell TransplantationPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2013
- Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients’ quality of lifeSupportive Care in Cancer, 2012
- Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline UpdateJournal of Oncology Practice, 2011
- Delayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only)Supportive Care in Cancer, 2010
- The NK1 receptor antagonist aprepitant does not alter the pharmacokinetics of high‐dose melphalan chemotherapy in patients with multiple myelomaBritish Journal of Clinical Pharmacology, 2010
- Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantationAnnals of Oncology, 2010
- The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (highdose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combinationBone Marrow Transplantation, 2010
- Nausea and vomiting with high-dose chemotherapy and stem cell rescue therapy: a review of antiemetic regimensBone Marrow Transplantation, 2008
- Prospective evaluation of antiemetic outcome following high-dose chemotherapy with hematopoietic stem cell supportBone Marrow Transplantation, 2001
- Multiple myeloma treated with high dose intravenous melphalanBritish Journal of Haematology, 1987